{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:40Z","timestamp":1786980580297,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10198-023-01614-6","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:01:27Z","timestamp":1689080487000},"page":"641-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-9858","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Trouiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-6896","authenticated-orcid":false,"given":"Georgios F.","family":"Nikolaidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Macabeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Gerlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-1421","authenticated-orcid":false,"given":"Max","family":"Schlueter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Laramee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"1","key":"1614_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller, A.J., Mihm, M.C., Jr.: Melanoma. N Engl J Med. 355(1), 51\u201365 (2006)","journal-title":"N Engl J Med."},{"issue":"15","key":"1614_CR2","first-page":"210","volume":"3","author":"M Potrony","year":"2015","unstructured":"Potrony, M., Badenas, C., Aguilera, P., Puig-Butille, J.A., Carrera, C., Malvehy, J., et al.: Update in genetic susceptibility in melanoma. Ann Transl Med. 3(15), 210 (2015)","journal-title":"Ann Transl Med."},{"issue":"3","key":"1614_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4068\/cmj.2017.53.3.173","volume":"53","author":"S Ryu","year":"2017","unstructured":"Ryu, S., Youn, C., Moon, A.R., Howland, A., Armstrong, C.A., Song, P.I.: Therapeutic inhibitors against mutated BRAF and MEK for the treatment of metastatic melanoma. Chonnam Med J. 53(3), 173\u2013177 (2017)","journal-title":"Chonnam Med J."},{"key":"1614_CR4","unstructured":"American Cancer Society. Cancer Facts and Figures. 2022."},{"issue":"Suppl 5","key":"1614_CR5","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., Keilholz, U.: Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5), v126\u2013v132 (2015)","journal-title":"Ann Oncol."},{"key":"1614_CR6","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Cutaneous Melanoma. 2018."},{"key":"1614_CR7","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de dermatologie. Patients atteints de m\u00e9lanome de stade III inop\u00e9rable ou de stade IV. 2017."},{"issue":"3","key":"1614_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ad.2016.09.010","volume":"108","author":"P Serra-Arbeloa","year":"2017","unstructured":"Serra-Arbeloa, P., Rabines-Ju\u00e1rez, \u00c1.O., \u00c1lvarez-Ruiz, M.S., Guill\u00e9n-Grima, F.: Cost of cutaneous melanoma by tumor stage: a descriptive analysis. Actas Dermosifiliogr. 108(3), 229\u2013236 (2017)","journal-title":"Actas Dermosifiliogr."},{"issue":"9","key":"1614_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1080\/13696998.2016.1184155","volume":"19","author":"K Vouk","year":"2016","unstructured":"Vouk, K., Benter, U., Amonkar, M.M., Marocco, A., Stapelkamp, C., Pfersch, S., et al.: Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ. 19(9), 900\u2013912 (2016)","journal-title":"J Med Econ."},{"issue":"5","key":"1614_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R., Ascierto, P.A., Gogas, H.J., Arance, A., Mandala, M., Liszkay, G., et al.: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19(5), 603\u2013615 (2018)","journal-title":"Lancet Oncol."},{"issue":"10","key":"1614_CR11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R., Ascierto, P.A., Gogas, H.J., Arance, A., Mandala, M., Liszkay, G., et al.: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19(10), 1315\u20131327 (2018)","journal-title":"Lancet Oncol."},{"key":"1614_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","volume":"126","author":"PA Ascierto","year":"2020","unstructured":"Ascierto, P.A., Dummer, R., Gogas, H.J., Flaherty, K.T., Arance, A., Mandala, M., et al.: Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 126, 33\u201344 (2020)","journal-title":"Eur J Cancer."},{"key":"1614_CR13","doi-asserted-by":"crossref","unstructured":"Dummer R, Flaherty K, Robert C, Arance AM, Groot JWd, Garbe C, et al. Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. Journal of Clinical Oncology. 2021;39 (15_suppl):9507.","DOI":"10.1200\/JCO.2021.39.15_suppl.9507"},{"key":"1614_CR14","unstructured":"Eudra CT Number 2011-006088-23. A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib andthe MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) ormetastatic (stage IV) BRAF V600E\/K mutation positive cutaneous melanoma."},{"issue":"7","key":"1614_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","volume":"36","author":"GV Long","year":"2018","unstructured":"Long, G.V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D.B., et al.: Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 36(7), 667\u2013673 (2018)","journal-title":"J Clin Oncol."},{"issue":"9","key":"1614_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto, P.A., McArthur, G.A., Dr\u00e9no, B., Atkinson, V., Liszkay, G., Di Giacomo, A.M., et al.: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17(9), 1248\u20131260 (2016)","journal-title":"Lancet Oncol."},{"issue":"33","key":"1614_CR17","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","volume":"38","author":"R Seth","year":"2020","unstructured":"Seth, R., Messersmith, H., Kaur, V., Kirkwood, J.M., Kudchadkar, R., McQuade, J.L., et al.: Systemic Therapy for Melanoma: ASCO Guideline. J. Clin. Oncol. 38(33), 3947\u20133970 (2020)","journal-title":"J. Clin. Oncol."},{"key":"1614_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102463","volume":"110","author":"P Corrie","year":"2022","unstructured":"Corrie, P., Meyer, N., Berardi, R., Guidoboni, M., Schlueter, M., Kolovos, S., et al.: Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treat Rev. 110, 102463 (2022)","journal-title":"Cancer Treat Rev."},{"key":"1614_CR19","unstructured":"Haute Autorite De Sante (HAS). BRAFTOVI\/MEKTOVI (encorafenib\/binimetinib), BRAF and MEK inhibitor combination: Transparency committee opinion summary. 2019."},{"issue":"51","key":"1614_CR20","doi-asserted-by":"publisher","first-page":"S667","DOI":"10.1016\/S0959-8049(16)31828-7","volume":"3","author":"R Dummer","year":"2015","unstructured":"Dummer, R., Sandhu, S., Hassel, J., Mu\u00f1oz, E., Berking, C., Gesierich, A., et al.: 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib\/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. Eur. J. Cancer 3(51), S667\u2013S668 (2015)","journal-title":"Eur. J. Cancer"},{"key":"1614_CR21","unstructured":"National Institute for Health and Care Excellence. NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. 2019."},{"issue":"11","key":"1614_CR22","doi-asserted-by":"publisher","first-page":"e2132262","DOI":"10.1001\/jamanetworkopen.2021.32262","volume":"4","author":"C Cai","year":"2021","unstructured":"Cai, C., Yunusa, I., Tarhini, A.: Estimated cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 variation Metastatic Melanoma. JAMA Network Open. 4(11), e2132262 (2021)","journal-title":"JAMA Network Open."},{"key":"1614_CR23","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. 2017."},{"key":"1614_CR24","unstructured":"National Institute for Health and Care Excellence. NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma. 2016."},{"key":"1614_CR25","unstructured":"National Institute for Health and Care Excellence. NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab. 2017."},{"key":"1614_CR26","unstructured":"Haute Autorite De Sante (HAS). Choices in methods for economic evaluation\u2014HAS. 2020."},{"key":"1614_CR27","unstructured":"Latimer N. Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. 2011."},{"key":"1614_CR28","unstructured":"Greenhalgh J, Mahon J, Beale S. Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID661]: A Single Technology Appraisa. 2016."},{"issue":"36","key":"1614_CR29","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 27(36), 6199\u20136206 (2009)","journal-title":"J Clin Oncol."},{"key":"1614_CR30","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques (INSEE). Tables de mortalit\u00e9 par niveau de vie. 2016."},{"issue":"5","key":"1614_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/annonc\/mdx040","volume":"28","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no, B., Ribas, A., Larkin, J., Ascierto, P.A., Hauschild, A., Thomas, L., et al.: Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 28(5), 1137\u20131144 (2017)","journal-title":"Ann Oncol."},{"key":"1614_CR32","unstructured":"National Institute for Health and Care Excellence. NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. 2016."},{"key":"1614_CR33","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Keytruda (pembrolizumab). Traitement adjuvant du m\u00e9lanome de stade III apr\u00e8s r\u00e9section compl\u00e8te. 2019."},{"issue":"1","key":"1614_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K-Y Liang","year":"1986","unstructured":"Liang, K.-Y., Zeger, S.L.: Longitudinal data analysis using generalized linear models. Biometrika 73(1), 13\u201322 (1986)","journal-title":"Biometrika"},{"key":"1614_CR35","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 1999."},{"issue":"5","key":"1614_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hec.678","volume":"11","author":"JS Hoch","year":"2002","unstructured":"Hoch, J.S., Briggs, A.H., Willan, A.R.: Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 11(5), 415\u2013430 (2002)","journal-title":"Health Econ."},{"issue":"4","key":"1614_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/hec.985","volume":"14","author":"K Claxton","year":"2005","unstructured":"Claxton, K., Sculpher, M., McCabe, C., Briggs, A., Akehurst, R., Buxton, M., et al.: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14(4), 339\u2013347 (2005)","journal-title":"Health Econ."},{"key":"1614_CR38","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011."},{"issue":"2","key":"1614_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7861\/clinmedicine.12-2-168","volume":"12","author":"KE Lacy","year":"2012","unstructured":"Lacy, K.E., Karagiannis, S.N., Nestle, F.O.: Advances in the treatment of melanoma. Clin Med (Lond). 12(2), 168\u2013171 (2012)","journal-title":"Clin Med (Lond)."},{"issue":"5","key":"1614_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s12094-020-02539-9","volume":"23","author":"M Majem","year":"2021","unstructured":"Majem, M., Manzano, J.L., Marquez-Rodas, I., Mujika, K., Mu\u00f1oz-Couselo, E., P\u00e9rez-Ruiz, E., et al.: SEOM clinical guideline for the management of cutaneous melanoma (2020). Clin Transl Oncol. 23(5), 948\u2013960 (2021)","journal-title":"Clin Transl Oncol."},{"issue":"1","key":"1614_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2019.07.003","volume":"23","author":"C Gorry","year":"2020","unstructured":"Gorry, C., McCullagh, L., Barry, M.: Economic evaluation of systemic treatments for advanced melanoma: a systematic review. Value in Health. 23(1), 52\u201360 (2020)","journal-title":"Value in Health."},{"key":"1614_CR42","doi-asserted-by":"crossref","unstructured":"Curl P, Vujic I, van \u2018t Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9 (9): e107255.","DOI":"10.1371\/journal.pone.0107255"},{"issue":"4","key":"1614_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40273-014-0241-z","volume":"33","author":"TE Delea","year":"2015","unstructured":"Delea, T.E., Amdahl, J., Wang, A., Amonkar, M.M., Thabane, M.: Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada. Pharmacoeconomics 33(4), 367\u2013380 (2015)","journal-title":"Pharmacoeconomics"},{"key":"1614_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/505302","volume":"2015","author":"V Shih","year":"2015","unstructured":"Shih, V., Ten Ham, R.M., Bui, C.T., Tran, D.N., Ting, J., Wilson, L.: Targeted therapies compared to dacarbazine for treatment of BRAF(V600E) metastatic melanoma: a cost-effectiveness analysis. J Skin Cancer. 2015, 505302 (2015)","journal-title":"J Skin Cancer."},{"key":"1614_CR45","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013."},{"key":"1614_CR46","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Mekinist (trametinib) en association au Tafinlar (dabrafenib). 2016."},{"key":"1614_CR47","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Cotellic (cobimetinib) en association \u00e0 Zelboraf (vemurafenib). 2016."},{"key":"1614_CR48","unstructured":"National Institute for Health and Care Excellence. NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation\u2011positive malignant melanoma. 2015."},{"key":"1614_CR49","unstructured":"National Institute for Health and Care Excellence. NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma. 2016."},{"key":"1614_CR50","unstructured":"National Institute for Health and Care Excellence. NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. 2014."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-023-01614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-023-01614-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-023-01614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T22:04:52Z","timestamp":1717020292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-023-01614-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1007\/s10198-023-01614-6","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JBT, BM, and PL were employees of Pierre Fabre Laboratories, Paris, France at the time of the development of this study. NM worked as an investigator and\/or speaker and\/or participated in advisory board and \/ or received research grants from BMS, MSD, Novartis, Pierre Fabre, Sun Pharma, Sanofi, Merck. GFN, LG, and MS were employees of IQVIA at the time of the development of this study and IQVIA received consulting fees from Pierre Fabre to support the manuscript development.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}